Pharmacoeconomic considerations of selective serotonin reuptake inhibitors (SSRIs) within the European Union

Journal of Medical Economics

Volumn 1, Issue 1-4, 1998, Pages 177-187

  Lopez Munoz F ^a   Echaniz T ^a   Sanz Galeote, J ^a   Rubio, G ^b   Alamo, C ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

cost treatment; depression; European Union; pharmacoeconomy; SSRI

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ARTICLE; AUSTRIA; DENMARK; DEPRESSION; DRUG COST; DRUG INDUSTRY; ECONOMIC EVALUATION; EUROPEAN UNION; FRANCE; GERMANY; GOVERNMENT; HUMAN; IRELAND; ITALY; NETHERLANDS; SPAIN; UNITED KINGDOM;

EID: 0031773137     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/199801177187     Document Type: Article

References (27)

1. Souetre E. Economic evaluation in mental disorders. Community versus Institutional care. Pharmaco Economics 1994;3:330-336.
2. Maynard A, Bloor K. Economic evaluation of mental health services. Current Opinion on Psychiatry 1995;8:122-125.
3. Henry JA, Rivas CA. Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Part 1: Depression and its treatment. Pharmaco Economics 1997;11:419-443. (Pubitemid 27240271)
4. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. The economic burden of depression in 1990. Journal of Clinical Psychiatry 1993;11:405-418. (Pubitemid 24020594)
5. Alamo C, López-Muñoz F, Cuenca E. Gli SSRI nella pratica clinica e la loro validità rispetto agli antidepressivi triciclici. Psichiatria & Medicina 1997;2:2.
6. Anderson MI, Tomenson BM. The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. Journal of Psychopharmacology 1994;8:238-249. (Pubitemid 24373793)
7. Martindale. The Extra Pharmacopoeia. 31th ed. London: Reynolds EF, 1996.
8. IMS (International Marketing Services) Iberica S. A. El Mercado Farmacéutico, Madrid, 1996.
9. Lepine JP, Gastpar M, Mendlewicz J, Tylee A. Depression in the community: The first pan-European study DEPRES (Depression Research in European Society). International Clinical Psychopharmacology 1997;12:19-29. (Pubitemid 27171192)
10. López-Muñoz F, Alamo C. Los estudios farmacoeconó micos en psiquiatría: análisis bibliométrico. Farmacoeconomía 1995; IV: 25-38.
11. Kind P, Sorensen J. The cost of depression. International Clinical Psychopharmacology 1993;7:191-195.
12. IMS (International Marketing Services) AG. R&D focus. London: IMS world Publications Ltd, 1997.
13. Henry JA. Debits and credits in the management of depression. British Journal of Psychiatry 1993; (suppl. Jul.): 33-39. (Pubitemid 23189557)
14. University of Leeds. The Treatment of Depression in Primary Care. Effective Health Care Bulletin, No 5, 1993.
15. FARMAINDUSTRIA: La Industria farmacéutica en cifras, Madrid, 1997.
16. Le Pen C, Levy E, Ravily V, Beuzen JN, Meurgey F. The cost of treatment dropout in depression. Journal of Affective Disorders 1994;31:1-18.
17. Jönsson B, Bebbington PE. What price depression? British Journal of Psychiatry 1994;164:665-673.
18. Beuzen JN, Ravily VF, Souetre EJ. Impact of fluoxetine on work loss in depression. International Clinical Psychopharmacology 1993;8:319-321. (Pubitemid 23301130)
19. Skaer TL, Sclar DA, Robison LM, Galin RS, Legg RF, Nemic NL. Economic evaluation of amitriptyline, desipramine, nortriptyline, and sertraline in the management of patients with depression. Current Therapeutic Research 1995;56:556-567.
20. Sclar DA, Robinson LM, Skaer TL, Galin RS, Legg RF, Nemec NL, Hughes TE, Buesching DP, Morgan M. Antidepressant pharmacotherapy: Economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization. Journal of Internal Medical Research 1995;23:395-412. (Pubitemid 26003141)
21. Revicki DA, Brown RE, Keller MB, Gonzales J, Culpepper L, Hales RE. Cost-effectiveness of newer antidepressants in managed care settings. Journal of Clinical Psychiatry 1997;58:47-58.
22. D'Mello DA, Finkbeiner DS, Kocher KN. The cost of antidepressant overdose. General Hospital Psychiatry 1995;17:454-455. (Pubitemid 26001570)
23. Revicki DA, Palmer CS, Phillips SD, Reblando JA, Heiligenstein JH, Brent J, Kulig K. Acute medical costs of fluoxetine versus tricyclic antidepressants. A prospective multicenter study of antidepressant drug overdoses. Pharmaco Economics 1997;11:48-55. (Pubitemid 27032249)
24. Stewart A. Revisiting the relative cost-effectiveness of selective serotonin re-uptake inhibitors and tricyclic antidepressants. What price inflation and subtherapeutic dosages? British Journal of Medical Economics 1996;10:409-431.
25. Freemantle N, House A, Song F, Mason JM, Sheldon TA. Prescribing selective serotonin reuptake inhibitors as strategy for prevention of suicide. British Medical Journal 1994;309:249-253. (Pubitemid 24252664)
26. Guze BH. Selective serotonin reuptake inhibitors. Assessment for formulary inclusion. Pharmaco Economics 1996;9:430-442.
27. Anton SF, Revicki DA. The use of decision analysis in the pharmacoeconomic evaluation of an antidepressant: a cost-effectiveness study of nefazodone. Psychopharmacology Bulletin 1995;31:249-258.